RxDoctor Payments Data

Sarah Hill, NP

Family · Biloxi, MSNPI 1891157467

Payments from drug & device makers

$2,632in general payments, 2019–2025

Across 157 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$775
  • Pfizer$303
  • Novo Nordisk$229
  • Lilly USA, LLC$183
  • Amgen$104
  • AstraZeneca$103
  • plus $936 from 27 others

What the payments were for

  • Food & beverage$2,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,632 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$103,260
Medicare patients
372
Services billed
1,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$48,616
OzempicSemaglutide32$41,033
JardianceEmpagliflozin28$23,046
LinzessLinaclotide13$18,157
TrulicityDulaglutide11$13,200
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,150
XareltoRivaroxaban11$10,264
MyrbetriqMirabegron12$6,066
Breo ElliptaFluticasone/Vilanterol12$4,620
Aripiprazole15$1,996
Atorvastatin Calcium223$1,890
Gabapentin81$1,860
Bupropion XlBupropion Hcl107$1,728
Albuterol Sulfate HfaAlbuterol Sulfate53$1,601
Pregabalin25$1,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$183$61,81647 claims
Novo NordiskOzempic$229$41,03332 claims
Boehringer IngelheimJardiance$98$23,04628 claims
AbbVieLinzess, Synthroid$775$19,07630 claims
GSKTrelegy Ellipta, Breo Ellipta$62$16,77131 claims
Johnson & JohnsonXarelto$56$10,26411 claims
Astellas Pharma US IncMyrbetriq$100$6,06612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Biloxi

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →